N-(3-Phenylphenyl)-(2-chloro-5-nitrophenyl)carboxamide | 372093-17-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3-Phenylphenyl)-(2-chloro-5-nitrophenyl)carboxamide
• 英文别名: 2-chloro-5-nitro-N-(3-phenylphenyl)benzamide
• CAS: 372093-17-9
• 化学式: C₁₉H₁₃ClN₂O₃
• 分子量: 352.777
• InChiKey: DESXUVPCYBWBRA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  74.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-氨基联苯 、 2-氯-5-硝基苯甲酰氯 在 tertiary amine 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以56%的产率得到N-(3-Phenylphenyl)-(2-chloro-5-nitrophenyl)carboxamide
  参考文献：
  名称：

  Optimization of Chloronitrobenzamides (CNBs) as Therapeutic Leads for Human African Trypanosomiasis (HAT)

  摘要：

  We previously reported the discovery of the activity of chloronitrobenzamides (CNBs) against bloodstream forms of Trypanosoma brucei. Herein we disclose extensive structure activity relationship and structure property relationship studies aimed at identification of tractable early leads for clinical development. These studies revealed a promising lead compound, 17b, that exhibited nanomolar potency against T. brucei (EC50 = 27 nM for T. b. brucei, 7 nM for T. b. rhodesiense, and 2 nM for T. b. gambiense) with excellent selectivity for parasite cells relative to mammalian cell lines (EC50 > 25 mu M). In addition compound 17b displayed suitable physiochemical characteristics and microsomal stability (t(1/2) > 4 h for human and mouse) to justify pursuing in vivo studies.

  DOI：

  10.1021/jm301687p

文献信息

• PPAR-gamma modulator
  申请人：SANKYO COMPANY, LIMITED

  公开号：US20030134859A1

  公开（公告）日：2003-07-17

  A compound of the following formula or a pharmacologically acceptable salt thereof: 1 wherein A represents a phenyl group or the like, B represents an aryl group or the like, X represents an oxygen atom or the like, and n represents 0 or 1. The compound is a PPAR &ggr; modulator which is a therapeutic agent for retrograde osteoporosis in which excessive differentiation of adipocytes is inhibited and formation and differentiation of osteoblasts from stem cells is facilitated, and for diabetes mellitus without characteristics such as excessive adipogenesis, liver dysfunction, vascular disorders, heart diseases and the like.

  以下化学式的化合物或其药理学上可接受的盐：其中A代表苯基或类似物，B代表芳基或类似物，X代表氧原子或类似物，n代表0或1。该化合物是一种PPAR &ggr; 调节剂，用于治疗逆行性骨质疏松症，通过抑制脂肪细胞的过度分化并促进干细胞向成骨细胞的形成和分化，以及用于糖尿病而不具有过度脂肪生成、肝功能障碍、血管紊乱、心脏疾病等特征。
• PPAR (GAMMA) MODULATORS
  申请人：Sankyo Company, Limited

  公开号：EP1277729A1

  公开（公告）日：2003-01-22

  [Subject] The present invention has a purpose for providing a PPAR γ modulator which can be a therapeutic agent for retrograde osteoporosis in which excessive differentiation of adipocytes was inhibited and formation and differentiation of osteoblasts from stem cells is facilitated or that for diabetes mellitus without characteristics such as excessive adipogenesis, liver dysfunction, vascular disorders, heart diseases and the like. [Solution] A compound of the following formula or a pharmacologically acceptable salt thereof: wherein A represents a phenyl group or the like, B represents an aryl group or the like, X represents an oxygen atom or the like, and n represents 0 or 1.

  主题 本发明的目的在于提供一种PPAR γ调节剂，该调节剂可作为逆行性骨质疏松症的治疗药物，在逆行性骨质疏松症中，脂肪细胞的过度分化受到抑制，而干细胞的成骨细胞的形成和分化得到促进，或者可作为无过度脂肪生成、肝功能障碍、血管紊乱、心脏病等特征的糖尿病的治疗药物。 [解决方案］ 下式化合物或其药理学上可接受的盐： 其中 A 代表苯基或类似物，B 代表芳基或类似物，X 代表氧原子或类似物，n 代表 0 或 1。
• Optimization of Chloronitrobenzamides (CNBs) as Therapeutic Leads for Human African Trypanosomiasis (HAT)
  作者：Jong Yeon Hwang、David Smithson、Fangyi Zhu、Gloria Holbrook、Michele C. Connelly、Marcel Kaiser、Reto Brun、R. Kiplin Guy

  DOI：10.1021/jm301687p

  日期：2013.4.11

  We previously reported the discovery of the activity of chloronitrobenzamides (CNBs) against bloodstream forms of Trypanosoma brucei. Herein we disclose extensive structure activity relationship and structure property relationship studies aimed at identification of tractable early leads for clinical development. These studies revealed a promising lead compound, 17b, that exhibited nanomolar potency against T. brucei (EC50 = 27 nM for T. b. brucei, 7 nM for T. b. rhodesiense, and 2 nM for T. b. gambiense) with excellent selectivity for parasite cells relative to mammalian cell lines (EC50 > 25 mu M). In addition compound 17b displayed suitable physiochemical characteristics and microsomal stability (t(1/2) > 4 h for human and mouse) to justify pursuing in vivo studies.